NASDAQ:IMRX

Immuneering Q3 2026 Earnings Results & Report

Immuneering logo
$3.46 -0.06 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$3.46 +0.00 (+0.14%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immuneering missed analyst earnings expectations in its Q3 2026 results, released October 29, 2026. The company reported EPS of -$0.37 versus the -$0.3050 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Immuneering EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.3050
Beat/Miss
Missed by -$0.0650
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Q3 2026 Earnings FAQ

Immuneering (NASDAQ:IMRX) reported earnings of -$0.37 per share for Q3 2026, missing the consensus estimate of -$0.3050. The report was announced on Thursday, October 29, 2026.

Immuneering Earnings Headlines

Transcript : Immuneering Corporation - Special Call
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for $29.97, but it's available as a free download for a limited time.tc pixel
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) is a clinical-stage biotechnology company developing medicines for cancer. The company uses computational biology and drug-discovery approaches to study disease patterns and identify potential therapeutic targets, with a focus on the MAPK signaling pathway, which is involved in many cancers.

Its lead drug candidate, atebimetinib (IMM-1-104), is an oral investigational therapy designed to inhibit MEK proteins and disrupt MAPK signaling. Immuneering is evaluating this candidate for solid tumors, including pancreatic cancer, and is advancing additional drug candidates aimed at cancer-related pathways.

Founded in 2008, Immuneering is headquartered in Cambridge, Massachusetts. Co-founder Benjamin Zeskind serves as the company’s chief executive officer.

View Immuneering Profile